Back to Research Hub
Neurocrine Biosciences, Inc.
NBIX
$165.24+2.12 (+1.30%)
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.
StreetsValue research for Neurocrine Biosciences, Inc. (NBIX)
Members get the full report for Neurocrine Biosciences, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.